Hafida El Ghachi

Hafida El Ghachi

Auto-generated profile, based on publicly available information

Hafida El Ghachi

Faculty of Sciences Semlalia, Cadi Ayyad University, Morocco

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2023
Verified
Book Chapter
Closed access
BEBilal El-Mansoury
Bilal El-Mansoury
KSKamal Smimih
Kamal Smimih
AKAbdelaati El Khiat
Abdelaati El Khiat
HFHanane El Fatimi
Hanane El Fatimi
AAAbdelmohcine Aimrane
Abdelmohcine Aimrane
AZAbdeljalil Zoubadi
Abdeljalil Zoubadi
Parkinson disease (PD) is the second most common neurodegenerative disease worldwide. It is characterized by both motor and non-motor symptoms. The histopathological hallmark of PD is the loss of dopaminergic neurons from the substantia nigra combined with Lewy bodies (LBs) and Lewy neurites, together termed Lewy pathology. However, the exact pathophysiological mechanism underpinning PD remains undetermined. Compelling evidence highlights the potential involvement of gut microbiota dysbiosis in the pathogenesis of PD and point toward potential pathological mechanisms between the gastrointestinal tract and the brain. In this regard, microbiota-targeted interventions such as probiotics and fecal microbiota transplantation (FMT) have been recently demonstrated to have a beneficial role in alleviating PD symptoms and providing neuroprotection. This chapter briefly provides an overview of current knowledge on disturbed gut microbiota and the gut-brain axis in PD, followed by possible therapeutic interventions, with a particular focus on the use of probiotics and FMT. Request access from your librarian to read this chapter's full text.


30 June 2023
Verified
Book Chapter
Closed access
HGHafida El Ghachi
Hafida El Ghachi
MOMjid OUKHRIB
Mjid OUKHRIB
LTLahcen Tamegart
Lahcen Tamegart
AMAbdelali Ben Maloui
Abdelali Ben Maloui
BEBilal El-Mansoury
Bilal El-Mansoury
HGHalima Gamrani
Halima Gamrani
Parkinson's disease is known by tremor, rigidity, and bradykinesia. Non-motor symptoms also manifest during the disease course or even predate the appearance of motor-symptoms and that can be as troublesome as motor features. At the cellular level, the degeneration of substantia nigra neurons and the low levels of dopamine caused by intracytoplasmic inclusions of Lewy bodies that consist of α-synuclein were recognized as the putative cause of the disease and therefore physical symptoms. PD is a slow-moving illness and detection of that disease is not easy because of delayed symptoms, variation in clinical manifestations, course of progression, and biomarker profiles from person to person. Early diagnosis of PD plays a critical role in effective disease management. Here, the authors aim to give an overview of different methods of diagnosing PD with emphasis on clinical differential diagnosis that differentiate it from other parkinsonian disorders, challenges, and a brief description of new approaches of artificial intelligence technologies as a tool for better prediction of that disease. Request access from your librarian to read this chapter's full text.

4 August 2023
Verified
Book Chapter
Closed access
MOMjid OUKHRIB
Mjid OUKHRIB
LTLahcen Tamegart
Lahcen Tamegart
HGHafida El Ghachi
Hafida El Ghachi
AMAbdelali Ben Maloui
Abdelali Ben Maloui
BEBilal El-Mansoury
Bilal El-Mansoury
HGHalima Gamrani
Halima Gamrani
Just after Alzheimer's disease, Parkinson's disease (PD) is considered the second most prevalent chronic and progressive neurodegenerative disorder with an increased prevalence in the elderly population, affecting men slightly more frequently than women, and often resulting in disability, dependence on care, reduced quality of life, and premature death. Regarding the etiology of PD, it is a complex disease involving both genetic and lifestyle factors as well as environmental factors. In addition to the cardinal motor symptoms, non-motor symptoms and comorbidities of PD are increasingly recognized as central to the disease. These include somatic symptoms, such as pain and autonomic dysfunction (orthostatic hypotension, bladder dysfunction, and constipation), and behavioral problems, such as dementia, impulse control disorders, sleep disorders, fatigue, and psychosis. The epidemiological study of the different symptoms and comorbidities related to PD helps to understand their causes and consequently to know how to reduce the incidence and impact of these dysfunctions in the disease. Request access from your librarian to read this chapter's full text.

30 June 2023
Verified
Book Chapter
Closed access
AMAbdelali Ben Maloui
Abdelali Ben Maloui
BEBilal El-Mansoury
Bilal El-Mansoury
YHYoussef Ait Hamdan
Youssef Ait Hamdan
MOMjid OUKHRIB
Mjid OUKHRIB
HGHafida El Ghachi
Hafida El Ghachi
HGHalima Gamrani
Halima Gamrani
Stem cells are defined by their ability of self-renewal and generation of differentiated functional cell types, which are derived from the embryo and various postnatal animal sources. These cells can be divided according to their developmental potential into totipotent, unipotent, multipotent, and pluripotent, which may be of embryonic, fetal, or adult origin. These stem cells are an effective way to explore human diseases and their treatment, especially neurodevelopmental disorders. Therefore, stem cells used for cell therapy in Parkinson's disease (PD) are mainly embryonic stem cells (ES Cells), fetal neural stem cells (NSCs), adult neural stem cells, mesenchymal stem cells (MSCs) because of their plasticity, and induced pluripotent stem cells (iPSCs). They are theoretically capable of forming dopaminergic neurons that may be implanted in patients with Parkinson's disease. This chapter presents the primordial role of cell therapy by stem cells in the mechanism of Parkinson's disease, also in dopamine cell replacement based on generating neurons. Request access from your librarian to read this chapter's full text.

19 June 2025 in Natural Product Communications
Verified
Journal Article
Open access
HGHafida El Ghachi
Hafida El Ghachi
MOMjid OUKHRIB
Mjid OUKHRIB
KBKarima Benrazzouk
Karima Benrazzouk
LBLoubna Boukhzar
Loubna Boukhzar
HGHalima Gamrani
Halima Gamrani
RSRachid Soulimani
Rachid Soulimani
Background and objectives: The therapeutic properties of local Cannabis sativa varieties remain underexplored. This study aimed to evaluate the antinociceptive effects of a Moroccan C. sativa ethanolic extract (CEE) in acute pain models. Methods: Phytochemical analysis of CEE was conducted using HPLC, and antioxidant activity was assessed via DPPH and FRAP assays. Antinociceptive effects were evaluated using writhing and formalin tests after a single oral administration. Mice treated with CEE (30 mg/kg) or cannabidiol (CBD; 30 mg/kg) were compared to a diclofenac-treated group (10 mg/kg). Both treatments were tested for cannabinoid receptor-1 effects known as the cannabinoid tetrad. Results: Of several polyphenolic compounds identified from CEE, kaempferol formed the main component. In vitro, CEE exhibited antioxidant activity, with IC 50 values of 289.01 ± 0.003 μg/mL in the DPPH assay and 57.29 ± 6.7 μg/mL in the FRAP assay. Both CEE and CBD significantly reduced writhing responses, paw licking/biting time, and paw swelling, indicating antinociceptive and anti-inflammatory effects. The histopathological analysis supported these findings. Neither CEE nor CBD induced cannabinoid tetrad-related effects. Conclusions: CEE exhibited significant antinociceptive and anti-inflammatory activities comparable to CBD and diclofenac, without cannabinoid tetrad-associated symptoms. Moroccan C. sativa extract shows promise for developing novel anti-inflammatory drugs.